PIPELINE

Investigational Products

DUR-928 Injectable
Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Alcoholic hepatitis (AH)

DUR-928 Injectable
Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: COVID-19 Associated Acute Liver or Kidney Injury

DUR-928 Oral
Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Nonalcoholic steatohepatitis (NASH)

POSIMIR® (bupivacaine extended-release solution)
Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Postoperative pain

ORADURTM-Methylphenidate ER
Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Attention-deficit hyperactivity disorder (ADHD)

*Phase III study conducted in Taiwan. Approved in Taiwan as Methydur Sustained Release Capsules. Not approved in any other country.